XML 18 R8.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Cash, Cash Equivalents and Investments | 9 Months Ended
--- | ---
Sep. 30, 2018
Cash, Cash Equivalents and Investments |
Cash, Cash Equivalents and Investments | NOTE 3. CASH, CASH EQUIVALENTS AND INVESTMENTS Securities classified as cash, cash equivalents and short-term investments as of September 30, 2018 and December 31, 2017, are summarized below (in thousands). Estimated fair value is based on quoted market prices for these investments.
|  | September 30, 2018
|  |  |  | Gross Unrealized |  |  |
|  | Amortized Cost |  | Gains |  | Losses |  | Fair Value
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 2,787 |  |  | — |  |  | — |  | $ | 2,787
Money market funds |  |  | 66,235 |  |  | — |  |  | — |  |  | 66,235
Corporate bonds |  |  | 1,999 |  |  | — |  |  | — |  |  | 1,999
Commercial paper |  |  | 3,994 |  |  | — |  |  | — |  |  | 3,994
Total cash and cash equivalents |  | $ | 75,015 |  | $ | — |  | $ | — |  | $ | 75,015
Short-term investments |  |  |  |  |  |  |  |  |  |  |  |
U.S. treasury securities |  |  | 7,959 |  |  | — |  |  | (2) |  |  | 7,957
Corporate bonds |  |  | 34,449 |  |  | — |  |  | (9) |  |  | 34,440
Commercial paper |  |  | 61,116 |  |  | — |  |  | (5) |  |  | 61,111
Asset-backed securities |  |  | 7,884 |  |  | — |  |  | (1) |  |  | 7,883
Total short-term investments |  | $ | 111,408 |  | $ | — |  | $ | (17) |  | $ | 111,391
Total cash equivalents and investments |  | $ | 186,423 |  | $ | — |  | $ | (17) |  | $ | 186,406
|  | December 31, 2017
|  |  |  | Gross Unrealized |  |  |
|  | Amortized Cost |  | Gains |  | Losses |  | Fair Value
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 5,882 |  | $ | — |  | $ | — |  | $ | 5,882
Money market funds |  |  | 68,651 |  |  | — |  |  | — |  |  | 68,651
Commercial paper |  |  | 850 |  |  | — |  |  | — |  |  | 850
Total cash equivalents and investments |  | $ | 75,383 |  | $ | — |  | $ | — |  | $ | 75,383
Short-term investments |  |  |  |  |  |  |  |  |  |  |  |
U.S. treasury securities |  | $ | 3,994 |  |  | — |  |  | (1) |  | $ | 3,993
Corporate bonds |  |  | 26,853 |  |  | — |  |  | (26) |  |  | 26,827
Commercial paper |  |  | 19,584 |  |  | — |  |  | (14) |  |  | 19,570
Asset-backed securities |  |  | 8,209 |  |  | — |  |  | (6) |  |  | 8,203
Total short-term investments |  | $ | 58,640 |  | $ | — |  | $ | (47) |  | $ | 58,593
Total cash equivalents and investments |  | $ | 134,023 |  | $ | — |  | $ | (47) |  | $ | 133,976
Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. The Company invests its cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in “accumulated other comprehensive loss” within stockholders’ equity on the Company’s condensed consolidated balance sheets. The Company uses the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in “other income, net” in the consolidated condensed statement of operations. All available-for-sale securities held as of September 30, 2018, had contractual maturities of less than one year. The Company’s available-for-sale securities are subject to a periodic impairment review. The Company considers a debt security to be impaired when its fair value is less than its carrying cost, in which case the Company would further review the investment to determine whether it is other-than-temporarily impaired. When the Company evaluates an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not the Company will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, the Company writes it down through the statement of operations to its fair value and establishes that value as a new cost basis for the investment. The Company did not identify any of its available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of September 30, 2018, no investment was in a continuous unrealized loss position for more than one year and the Company believes that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.

X
- References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -URI http://asc.fasb.org/topic&trid=2122426 + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration